GT Biopharma Inc (GTBP)

[oxis007]

You should be fine, like others have said on the board, your new cost per share will be about $8.04 per share. However after this reverse spit they will uplist to the nasdaq. The reason I know for sure that they are uplisting is because they will finally have a new CEO. Kathleen Clarence-Smith, MD, PhD is the new CEO, and all the companies she has run prior to acquisition have been on the nasdaq. Also keep in mind that the new CMO (my guess Mace Rothenberg) used to be the CMO of Pfizer, whom I can guarantee has no interest in running a penny-stock company.

When you get a chance check out the summer presentations on the Oxis website.

OXS-3550 TriKE
OXS-1615 TetraKE for Carcinoma
PainBrake for Chronic Neuropathic Pain

These are the three drugs where the value in the company is.

OXS-3550 TriKE has been proven to superior to OXS-1550 in in vivo studies, so I don't expect OXS-1550 to pass Phase II trials, however OXS-3550 TriKE most likely will. As it has been proven to be more effective than Rituxan in killing cancer cells.

As for PainBrake, I believe that that will be licensed out to a larger pharmaceutical company for 100 million with another potential 500 million should the drug be approved.